Biotechnology Portfolio Financial Statements From 2010 to 2024
| FBIOX Fund | USD 20.50 0.29 1.39% |
Check Biotechnology Portfolio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Biotechnology Portfolio's main balance sheet or income statement drivers, such as , as well as many indicators such as . Biotechnology financial statements analysis is a perfect complement when working with Biotechnology Portfolio Valuation or Volatility modules.
Biotechnology |
Biotechnology Portfolio Biotechnology Mutual Fund Price To Sales Analysis
Biotechnology Portfolio's Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Biotechnology Portfolio Price To Sales | 7.71 X |
Most of Biotechnology Portfolio's fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Biotechnology Portfolio Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
| Competition |
Based on the latest financial disclosure, Biotechnology Portfolio Biotechnology has a Price To Sales of 7.71 times. This is much higher than that of the Fidelity Investments family and significantly higher than that of the Health category. The price to sales for all United States funds is notably lower than that of the firm.
Biotechnology Portfolio Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Biotechnology Portfolio's current stock value. Our valuation model uses many indicators to compare Biotechnology Portfolio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biotechnology Portfolio competition to find correlations between indicators driving Biotechnology Portfolio's intrinsic value. More Info.Biotechnology Portfolio Biotechnology is one of the top funds in price to earning among similar funds. It also is one of the top funds in price to book among similar funds fabricating about 0.12 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Biotechnology Portfolio Biotechnology is roughly 8.52 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biotechnology Portfolio's earnings, one of the primary drivers of an investment's value.About Biotechnology Portfolio Financial Statements
Biotechnology Portfolio investors use historical fundamental indicators, such as Biotechnology Portfolio's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Biotechnology Portfolio. Please read more on our technical analysis and fundamental analysis pages.
The fund invests primarily in common stocks. It normally invests at least 80 percent of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuers financial condition and industry position, as well as market and economic conditions to select investments. The fund is non-diversified.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Biotechnology Mutual Fund
Biotechnology Portfolio financial ratios help investors to determine whether Biotechnology Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biotechnology with respect to the benefits of owning Biotechnology Portfolio security.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |